PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27188205-3 2017 MATERIALS AND METHODS: CD can convert a prodrug, 5-fluorocytosine (5-FC), to active 5-fluorouracil, which inhibits tumor growth through the inhibition of DNA synthesis,while IFN-beta also strongly inhibits tumor growth by inducing the apoptotic process. Fluorouracil 84-98 interferon beta 1 Homo sapiens 174-182 9815929-8 1995 When the prolonged infusion of IFN-beta followed a 1-h exposure to FUra, the observed TS inhibition and recovery, at each time point, were very similar to the expected values, indicating that the interactions between these drugs at the level of TS are not the determinant of the synergism. Fluorouracil 67-71 interferon beta 1 Homo sapiens 31-39 9815929-10 1995 During the continuous exposure to IFN-beta, a significant accumulation of HCT-8 cells in S-phase was observed at 24, 48, and 72 h compared to untreated controls (P = 0.003); however, under the same experimental conditions producing synergy in the clonogenic assay, no significant cell cycle perturbations were produced by the combination of FUra followed by IFN-beta compared to those caused by each agent alone. Fluorouracil 341-345 interferon beta 1 Homo sapiens 34-42 9815929-15 1995 These results suggest that the mechanism of this synergism may be related to the ability of IFN-beta to promote the incorporation of intracellular FUra metabolites into nucleic acids and/or to inhibit the cleavage of FUra nucleotides from RNA/DNA. Fluorouracil 147-151 interferon beta 1 Homo sapiens 92-100 8517649-0 1993 Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Fluorouracil 48-62 interferon beta 1 Homo sapiens 0-15 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 104-118 interferon beta 1 Homo sapiens 50-65 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 104-118 interferon beta 1 Homo sapiens 67-75 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 120-124 interferon beta 1 Homo sapiens 50-65 8517649-1 1993 The modulating effect of human fibroblast-derived interferon beta (IFN-beta) on the antitumor effect of 5-fluorouracil (5-FU) against human colon carcinoma cells in vitro and in vivo was investigated. Fluorouracil 120-124 interferon beta 1 Homo sapiens 67-75 25963746-12 2015 5-FU increased the IFN-beta/receptor 2 (IFNAR2) and BXA levels, indicating that 5-FU increased sensitivity of endometrial cancer cells to IFN-beta, leading to apoptosis of cancer cells. Fluorouracil 0-4 interferon beta 1 Homo sapiens 19-27 25963746-12 2015 5-FU increased the IFN-beta/receptor 2 (IFNAR2) and BXA levels, indicating that 5-FU increased sensitivity of endometrial cancer cells to IFN-beta, leading to apoptosis of cancer cells. Fluorouracil 80-84 interferon beta 1 Homo sapiens 19-27 17572015-8 2007 IFN-beta with 10 muM of 5-FU frequently induced synergistic antiproliferative effects. Fluorouracil 24-28 interferon beta 1 Homo sapiens 0-8 24141111-8 2014 The tumor inhibitory effect was greater with the HB1.F3.CD.IFN-beta cells, indicating an additional effect of IFN-beta to 5-FU. Fluorouracil 122-126 interferon beta 1 Homo sapiens 59-67 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 343-357 interferon beta 1 Homo sapiens 90-105 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 343-357 interferon beta 1 Homo sapiens 107-115 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 359-363 interferon beta 1 Homo sapiens 90-105 23403306-2 2013 In this study, we introduced the human parental neural stem cells, HB1.F3, with the human interferon beta (IFN-beta) gene which is a typical cytokine gene that has an antitumor effect and the cytosine deaminase (CD) gene from Escherichia coli (E. coli) that could convert the non-toxic prodrug, 5-fluorocytosine (5-FC), to a toxic metabolite, 5-fluorouracil (5-FU). Fluorouracil 359-363 interferon beta 1 Homo sapiens 107-115 23403306-6 2013 In particular, HB1.F3.CD.IFN-beta cells showed the synergistic cytotoxic activity of 5-FU and IFN-beta. Fluorouracil 85-89 interferon beta 1 Homo sapiens 25-33 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Fluorouracil 217-231 interferon beta 1 Homo sapiens 118-126 14654475-6 2003 As for IFN-alpha, synergistic effects were observed when combined with 5-FU and DOX on PLC/PRF/5 cells only, whereas IFN-beta showed synergistic effects with 5-FU and CDDP on HuH7 and PLC/PRF/5 cell lines. Fluorouracil 158-162 interferon beta 1 Homo sapiens 117-125 12396726-4 2002 In this report, we characterized the viability of various human tumor cells in vitro after combination treatment with IFN-beta protein and the chemotherapeutic drugs, cis-platinum (II) diamine dichloride (cisplatin), 5-fluorouracil (5-FU), paclitaxel (Taxol) and gemcitabine. Fluorouracil 233-237 interferon beta 1 Homo sapiens 118-126 10606259-1 1999 Interferons (IFN)-alpha, -beta, and -gamma enhance the activity of 5-fluorouracil (5-FU) in vitro and in vivo. Fluorouracil 67-81 interferon beta 1 Homo sapiens 0-42 10606259-1 1999 Interferons (IFN)-alpha, -beta, and -gamma enhance the activity of 5-fluorouracil (5-FU) in vitro and in vivo. Fluorouracil 83-87 interferon beta 1 Homo sapiens 0-42 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 158-172 interferon beta 1 Homo sapiens 84-99 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 158-172 interferon beta 1 Homo sapiens 105-113 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 174-178 interferon beta 1 Homo sapiens 84-99 9815298-1 1998 BACKGROUND: Preclinical and early clinical trials suggested that the biologic agent interferon beta ser (IFN beta ser) may augment the anticancer activity of 5-fluorouracil (5-FU). Fluorouracil 174-178 interferon beta 1 Homo sapiens 105-113 12168834-7 2002 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of liposome-entrapped-gene, the rate of growth inhibition of these cells increased over that caused by either 5-FU or hIFN-beta gene entrapped in the liposomes alone. Fluorouracil 51-65 interferon beta 1 Homo sapiens 230-239 12168834-7 2002 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of liposome-entrapped-gene, the rate of growth inhibition of these cells increased over that caused by either 5-FU or hIFN-beta gene entrapped in the liposomes alone. Fluorouracil 67-71 interferon beta 1 Homo sapiens 230-239 11848487-6 2001 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. Fluorouracil 51-65 interferon beta 1 Homo sapiens 115-124 11848487-6 2001 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. Fluorouracil 67-71 interferon beta 1 Homo sapiens 115-124 11848487-6 2001 When the esophageal cancer cells were treated with 5-fluorouracil (5-FU) in the presence of a low concentration of hIFN-beta, the effectiveness of 5-FU was markedly enhanced. Fluorouracil 147-151 interferon beta 1 Homo sapiens 115-124